Skip to main content

Advertisement

SpringerLink
Log in

Batimastat Nanoparticles Associated with Transcatheter Arterial Chemoembolization Decrease Hepatocellular Carcinoma Recurrence

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is a malignant tumor characterized by easy metastasis and frequent recurrence. Transarterial chemoembolization (TACE) remains the routine treatment for patients with HCC who are not eligible for surgical resection or percutaneous tumor ablation; however, 5-year survival rates following interventional therapy are only 17–38.8 %, with liver recurrence due to incomplete embolization and tumor angiogenesis being a significant reason for treatment failure. Ischemia and hypoxia induced by TACE is correlated with an increased expression of angiogenic factor and stimulates an increase in angiogenesis, including endothelial cells (ECs) proliferation. Matrix metalloproteinases (MMPs) are zinc-dependent proteolytic endopeptidases involved in tumor angiogenesis. In addition, MMPs stimulate tumor cell growth, migration and invasion, and metastasis. Hypoxia enhanced EC migration in a MMP-2-dependent manner while MMP inhibitors (MMPIs) significantly decreased the number of migrating cells in hypoxic cultures. We hypothesize batimastat (synthetic MMPI) nanoparticles associated with TACE could decrease HCC recurrence and metastasis. At first, batimastat nanoparticles were made from batimastat and poly(lactic-co-glycolic acid). Then, nanoparticles were mixed with lipiodol and chemotherapeutic drugs solution. The mixture was infused super-selectively into supplied artery of HCC through catheter. The disseminated area of batimastat might be same with TACE-induced hypoxia area. In the hypoxia area, batimastat inhibited the activity of MMPs, weakened the angiogenesis of tumor vascular system and migration of HCC cells. HCC cells could not escape from hypoxia area and tumor angiogenesis inhibited could not supply sufficient nutrients and O2 to residual HCC cells. With the help of batimastat, the killing effect of chemotherapeutic drugs might be enhanced. The rate of complete necrosis of HCC lesion might be increased and local recurrence and metastasis of HCC might be reduced. The hypothesis might increase the clinical efficacy of TACE and improve the prognosis of HCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Herszényi, L., & Tulassay, Z. (2010). Epidemiology of gastrointestinal and liver tumors. European Review for Medical and Pharmacological Science, 14, 249–258.

    Google Scholar 

  2. Zhou, W. P., Lai, E. C., Li, A. J., et al. (2009). A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Annals of Surgery, 249, 195–202.

    Article  PubMed  Google Scholar 

  3. Kanematsu, T., Furui, J., Yanaga, K., Okudaira, S., Shimada, M., & Shirabe, K. A. (2002). 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985–2000. Surgery, 131, S153–S158.

    Article  PubMed  Google Scholar 

  4. Kohno, H., Nagasue, N., Hayashi, T., et al. (1996). Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology, 43, 1405–1409.

    CAS  PubMed  Google Scholar 

  5. Lau, W. Y., Lai, E. C., Leung, T. W., & Yu, S. C. (2008). Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: A prospective randomized trial-update on 5-year and 10-year survival. Annals of Surgery, 247, 43–48.

    Article  PubMed  Google Scholar 

  6. Marelli, L., Stigliano, R., Triantos, C., et al. (2006). Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treatment Reviews, 32, 594–606.

    Article  CAS  PubMed  Google Scholar 

  7. Savastano, S., Feltrin, G. P., Neri, D., et al. (1993). Palliative treatment of hepatocellular carcinoma with transcatheter arterial embolization. Acta Radiologica, 34, 26–29.

    Article  CAS  PubMed  Google Scholar 

  8. Hsu, K. F., Chu, C. H., Chan, D. C., Yu, J. C., Shih, M. L., Hsieh, H. F., et al. (2012). Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class A liver function. European Journal of Radiology, 81, 466–471.

    Article  PubMed  Google Scholar 

  9. Takaki, S., Sakaguchi, H., Anai, H., et al. (2012). Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma. Cardiovascular and Interventional Radiology, 35, 544–554.

    Article  PubMed  Google Scholar 

  10. Poon, R. T., Ngan, H., Lo, C. M., Liu, C. L., Fan, S. T., & Wong, J. (2000). Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. Journal of Surgical Oncology, 73, 109–114.

    Article  CAS  PubMed  Google Scholar 

  11. Takayasu, K. (2010). Chemoembolization for unresectable hepatocellular carcinoma in Japan. Oncology, 78, 135–141.

    Article  PubMed  Google Scholar 

  12. Ben-Yosef, Y., Miller, A., Shapiro, S., & Lahat, N. (2005). Hypoxia of endothelial cells leads to MMP-2-dependent survival and death. American Journal of Physiology. Cell Physiology, 289, C1321–C1331.

    Article  CAS  PubMed  Google Scholar 

  13. Matrisian, L. M. (1992). The matrix-degrading metalloproteinases. BioEssays, 14, 455–463.

    Article  CAS  PubMed  Google Scholar 

  14. Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2, 161–174.

    Article  CAS  PubMed  Google Scholar 

  15. Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G., & Quaranta, V. (1997). Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science, 277, 225–228.

    Article  CAS  PubMed  Google Scholar 

  16. Levi, E., Fridman, R., Miao, H. Q., Ma, Y. S., Yayon, A., & Vlodavsky, I. (1996). Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proceedings of the National Academy of Sciences of the United States of America, 93, 7069–7074.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Bergers, G., Brekken, R., McMahon, G., et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2, 737–744.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Wang, Z. D., Huang, C., Li, Z. F., et al. (2010). Chrysanthemum indicum ethanolic extract inhibits invasion of hepatocellular carcinoma via regulation of MMP/TIMP balance as therapeutic target. Oncology Reports, 23, 413–421.

    CAS  PubMed  Google Scholar 

  19. Kaliski, A., Maggiorella, L., Cengel, K. A., et al. (2005). Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Molecular Cancer Therapeutics, 4, 1717–1728.

    Article  CAS  PubMed  Google Scholar 

  20. Mitsiades, N., Poulaki, V., Mitsiades, C. S., & Anderson, K. C. (2001). Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: New tricks from a (not so) old drug. Expert Opinion on Investigational Drugs, 10, 1075–1084.

    Article  CAS  PubMed  Google Scholar 

  21. Botos, I., Scapozza, L., Zhang, D., Liotta, L. A., & Meyer, E. F. (1996). Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proceedings of the National Academy of Sciences of the United States of America, 93, 2749–2754.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Bu, W., Tang, Z. Y., Sun, F. X., et al. (1998). Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology, 45, 1056–1061.

    CAS  PubMed  Google Scholar 

  23. Wojtowicz-Praga, S., Low, J., Marshall, J., et al. (1996). Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB94) in patients with advanced cancer. Investigational New Drugs, 14, 193–202.

    Article  CAS  PubMed  Google Scholar 

  24. Macaulay, V. M., O’Byrne, K. J., Saunders, M. P., et al. (1999). Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clinical Cancer Research, 5, 513–520.

    CAS  PubMed  Google Scholar 

  25. Beattie, G. J., & Smyth, J. F. (1998). Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clinical Cancer Research, 4, 1899–1902.

    CAS  PubMed  Google Scholar 

  26. Ogasawara, S., Yano, H., Momosaki, S., Nishida, N., Takemoto, Y., & Kojiro, M. (2005). Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. Oncology Reports, 13, 1043–1048.

    CAS  PubMed  Google Scholar 

  27. Kim, J. R., & Kim, C. H. (2004). Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells. International Journal of Biochemistry & Cell Biology, 36, 2293–2306.

    Article  CAS  Google Scholar 

  28. Ishii, Y., Nakasato, Y., Kobayashi, S., Yamazaki, Y., & Aoki, T. (2003). A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research, 22, 461–470.

    CAS  Google Scholar 

  29. Blanc, J. F., Bisson, C., Frankenne, F., et al. (2002). Hepatocarcinoma cell lines down-regulate matrix metalloproteinase-2 expression in human hepatic myofibroblasts. International Journal of Oncology, 20, 1129–1136.

    CAS  PubMed  Google Scholar 

  30. Guo, W. J., Li, J., Chen, Z., et al. (2004). Transient increased expression of VEGF and MMP-1 in a rat liver tumor model after hepatic arterial occlusion. Hepatogastroenterology, 51, 381–386.

    CAS  PubMed  Google Scholar 

  31. Miyoshi, A., Kitajima, Y., Ide, T., et al. (2006). Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner. International Journal of Oncology, 29, 1533–1539.

    CAS  PubMed  Google Scholar 

  32. Krüger, A., Kates, R. E., & Edwards, D. R. (2010). Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochimica et Biophysica Acta, 1803, 95–102.

    Article  PubMed  Google Scholar 

  33. Zucker, S., Cao, J., & Chen, W. T. (2000). Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene, 19, 6642–6650.

    Article  CAS  PubMed  Google Scholar 

  34. Hua, H., Li, M., Luo, T., Yin, Y., & Jiang, Y. (2011). Matrix metalloproteinases in tumorigenesis: An evolving paradigm. Cellular and Molecular Life Sciences, 68(23), 3853–3868.

    Article  CAS  PubMed  Google Scholar 

  35. Alwayn, I. P., Verbesey, J. E., Kim, S., et al. (2008). A critical role for matrix metalloproteinases in liver regeneration. Journal of Surgical Research, 145, 192–198.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This article was supported by research Grants from the Scientific Research Fund of Liaoning Science and Technology Agency, China (No. 2008225010-5) and the Scientific Research Fund of Liaoning Education Agency, China (No. 2007T183) and the Scientific Research Fund of First Hospital of CMU (No. FSFH1006).

Author information

Authors and Affiliations

  1. The First Hospital of China Medical University, No. 155, St Nanjingbei, Dist Heping, Shenyang, 110001, Liaoning, People’s Republic of China

    Liang Xiao & Man Wang

Authors
  1. Liang Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Man Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Liang Xiao.

Additional information

Liang Xiao and Man Wang contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xiao, L., Wang, M. Batimastat Nanoparticles Associated with Transcatheter Arterial Chemoembolization Decrease Hepatocellular Carcinoma Recurrence. Cell Biochem Biophys 70, 269–272 (2014). https://doi.org/10.1007/s12013-014-9893-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-9893-8

Keywords

Search

Navigation